Sirnaomics said this week that it has licensed a polypeptide nanoparticle delivery technology developed at the University of Maryland Medical School.
"The licensing agreement grants Sirnaomics exclusive rights to a patent covering use of histidine-lysine polymer for siRNA therapeutics in the areas of wound healing and ocular diseases," the company said.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
